Literature DB >> 32108008

Biological Signatures of Alzheimer's Disease.

Poornima Sharma1, Anjali Sharma2, Faizana Fayaz2, Sharad Wakode2, Faheem H Pottoo3.   

Abstract

Alzheimer's disease (AD) is the most prevalent and severe neurodegenerative disease affecting more than 0.024 billion people globally, more common in women as compared to men. Senile plaques and amyloid deposition are among the main causes of AD. Amyloid deposition is considered as a central event which induces the link between the production of β amyloid and vascular changes. Presence of numerous biomarkers such as cerebral amyloid angiopathy, microvascular changes, senile plaques, changes in white matter, granulovascular degeneration specifies the manifestation of AD while an aggregation of tau protein is considered as a primary marker of AD. Likewise, microvascular changes, activation of microglia (immune defense system of CNS), amyloid-beta aggregation, senile plaque and many more biomarkers are nearly found in all Alzheimer's patients. It was seen that 70% of Alzheimer's cases occur due to genetic factors. It has been reported in various studies that apolipoprotein E(APOE) mainly APOE4 is one of the major risk factors for the later onset of AD. Several pathological changes also occur in the white matter which include dilation of the perivascular space, loss of axons, reactive astrocytosis, oligodendrocytes and failure to drain interstitial fluid. In this review, we aim to highlight the various biological signatures associated with the AD which may further help in discovering multitargeting drug therapy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Alzheimer's disease; Cerebral amyloid angiopathy; Dementia; Microvascular degeneration; Neurodegenerative disorders; Neurofibrillary tangles.

Mesh:

Substances:

Year:  2020        PMID: 32108008     DOI: 10.2174/1568026620666200228095553

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  14 in total

Review 1.  Deciphering the Interacting Mechanisms of Circadian Disruption and Alzheimer's Disease.

Authors:  Md Sahab Uddin; Dewan Md Sumsuzzman; Philippe Jeandet; Tapan Behl; Abdur Rauf; Md Shah Amran; Ghulam Md Ashraf
Journal:  Neurochem Res       Date:  2021-04-19       Impact factor: 3.996

Review 2.  Exploring the Role of CLU in the Pathogenesis of Alzheimer's Disease.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Mst Marium Begum; Md Siddiqul Islam; Tapan Behl; Ghulam Md Ashraf
Journal:  Neurotox Res       Date:  2020-08-21       Impact factor: 3.911

Review 3.  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets.

Authors:  Md Sahab Uddin; Abdullah Al Mamun; Md Tanvir Kabir; Ghulam Md Ashraf; May N Bin-Jumah; Mohamed M Abdel-Daim
Journal:  Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.590

4.  Gut microbial involvement in Alzheimer's disease pathogenesis.

Authors:  Yu Zhang; Rulin Geng; Qiuyun Tu
Journal:  Aging (Albany NY)       Date:  2021-05-10       Impact factor: 5.682

Review 5.  Neuroinflammatory Signaling in the Pathogenesis of Alzheimer's Disease.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Maroua Jalouli; Md Ataur Rahman; Philippe Jeandet; Tapan Behl; Athanasios Alexiou; Ghadeer M Albadrani; Mohamed M Abdel-Daim; Asma Perveen; Ghulam Md Ashraf
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

Review 6.  S100A6 and Its Brain Ligands in Neurodegenerative Disorders.

Authors:  Anna Filipek; Wiesława Leśniak
Journal:  Int J Mol Sci       Date:  2020-06-01       Impact factor: 5.923

Review 7.  Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Md Sohanur Rahman; Tapan Behl; Philippe Jeandet; Ghulam Md Ashraf; Agnieszka Najda; May N Bin-Jumah; Hesham R El-Seedi; Mohamed M Abdel-Daim
Journal:  Int J Mol Sci       Date:  2020-08-14       Impact factor: 5.923

8.  A Network Pharmacology Approach to Estimate Potential Targets of the Active Ingredients of Epimedium for Alleviating Mild Cognitive Impairment and Treating Alzheimer's Disease.

Authors:  Xianwei Gao; Shengnan Li; Chao Cong; Yuejiao Wang; Lianwei Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-28       Impact factor: 2.629

9.  TSPO Ligands PK11195 and Midazolam Reduce NLRP3 Inflammasome Activation and Proinflammatory Cytokine Release in BV-2 Cells.

Authors:  Hao Feng; Yongxin Liu; Rui Zhang; Yingxia Liang; Lina Sun; Nannan Lan; Baoyu Ma
Journal:  Front Cell Neurosci       Date:  2020-12-10       Impact factor: 5.505

Review 10.  Neuroinflammation: A Potential Risk for Dementia.

Authors:  Md Afroz Ahmad; Ozaifa Kareem; Mohammad Khushtar; Md Akbar; Md Rafiul Haque; Ashif Iqubal; Md Faheem Haider; Faheem Hyder Pottoo; Fatima S Abdulla; Mahia B Al-Haidar; Noora Alhajri
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.